Table 4 Characteristics of patients with reactivated HBV after vaccination.

From: A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation

No.

Pt ID

Age

Sex

Disease

Stem cell source

Time to HBV reactivation (month)

HBV-DNA at reactivation (log IU/mL)

HBsAg at reactivation (IU/mL)

HBsAb at reactivation (mIU/mL)

ALT at reactivation (U/L)

HBV genotype

Immunosuppressant at reactivation

cGVHD

1

2

72

M

AML

allo BMT

27

1.6

(−)

60.9

10

N/A

PSL

(+)

2

13

34

M

CML

allo BMT

18

1.7

(−)

39.8

160

C

FK + PSL

(+)

3

17

58

M

NHL

allo BMT

20

1.6

(−)

1.1

21

N/A

FK + PSL

(−)

4

22

64

M

AML

allo BMT

14

1.4

(−)

1.6

23

N/A

FK + PSL

(+)

5

23

61

F

ALL

allo BMT

17

2.3

(−)

881

15

C

FK + PSL

(+)

6

42

52

M

NHL

allo PBSCT

14

4

(+) (2.17)

112

12

C

CyA + PSL

(+)

  1. AML acute myeloid leukemia, CML chronic myelogenous leukemia, NHL non Hodgkin lymphoma, ALL acute lymphocytic leukemia, BMT bone marrow transplantation, PBSCT peripheral blood stem cell transplantation, PSL prednisolone, FK tacrolimus, CyA cyclosporin.
Back to article page